A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Фаза 2
Идёт, набор закрыт
NCT02519348
| Заболевание | Hepatocellular Carcinoma |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | MedImmune LLC |
|---|
| Статус | Идёт, набор закрыт |
|---|
| Участники | 433 участн. |
|---|
| Вмешательство | Tremelimumab, Durvalumab, Bevacizumab |
|---|
| Дата начала | 19.10.2015 |
|---|
| Дата завершения | 6.11.2020 |
|---|
| Публикация результатов | 6.12.2021 |
|---|
Кратко
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.
Number of Participants With Dose Limiting Toxicities (DLTs)
From Day 1 to Day 28 after first dose of study drug · Participants
| Part 1A: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 0 Participants |
|---|
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) · Participants
| Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 38 Participants |
|---|
| Parts 2 and 3: Durvalumab 1500 mg | 95 Participants |
|---|
| Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg | 73 Participants |
|---|
| Parts 2 and 3: Tremelimumab 750 mg | 67 Participants |
|---|
| Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg | 80 Participants |
|---|
| Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg | 45 Participants |
|---|
Number of Participants With Clinically Important Changes in Hematology and Clinical Chemistry Parameters
From Day 1 through the 12 months after the first dose of study drug given to the last participant enrolled in the study (approximately 61 months) · Participants
| Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kg | 0 Participants |
|---|
| Parts 2 and 3: Durvalumab 1500 mg | 5 Participants |
|---|
| Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mg | 6 Participants |
|---|
| Parts 2 and 3: Tremelimumab 750 mg | 6 Participants |
|---|
| Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mg | 6 Participants |
|---|
| Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kg | 0 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.